ABBVIE
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 25
- Registration Number
- NCT02944396
- Locations
- 🇺🇸
University of Chicago /ID# 153824, Chicago, Illinois, United States
🇺🇸Duke University Medical Center /ID# 153821, Durham, North Carolina, United States
🇺🇸University of Alabama at Birmingham - Main /ID# 155135, Birmingham, Alabama, United States
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
- Conditions
- Myelodysplastic Syndromes (MDS)
- Interventions
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 129
- Registration Number
- NCT02942290
- Locations
- 🇺🇸
Tufts Medical Center /ID# 153672, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute /ID# 152735, Boston, Massachusetts, United States
🇺🇸University of Arizona Cancer Center - North Campus /ID# 154155, Tucson, Arizona, United States
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
- Conditions
- Hepatitis C Virus Infection
- Interventions
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 33
- Registration Number
- NCT02939989
- Locations
- 🇺🇸
Ruane Clinical Research Group /ID# 155714, Los Angeles, California, United States
🇨🇳Beijing Di Tan Hospital, Capital Medical University /ID# 218496, Beijing, China
🇨🇦University of Calgary /ID# 155726, Calgary, Alberta, Canada
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
- Conditions
- Uterine FibroidsHeavy Menstrual Bleeding
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 433
- Registration Number
- NCT02925494
- Locations
- 🇺🇸
Choice Research, LLC /ID# 153492, Dothan, Alabama, United States
🇺🇸NECCR Fall River LLC /ID# 153274, Fall River, Massachusetts, United States
🇺🇸Mount Vernon Clinical Res, LLC /ID# 153403, Atlanta, Georgia, United States
A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 167
- Registration Number
- NCT02925117
- Locations
- 🇺🇸
Advanced Medical Research /ID# 154516, Sandy Springs, Georgia, United States
🇺🇸ForCare Clinical Research /ID# 157974, Tampa, Florida, United States
🇺🇸DermAssociates /ID# 153584, Rockville, Maryland, United States
HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
- Conditions
- Uveitis
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 259
- Registration Number
- NCT02916017
- Locations
- 🇯🇵
Nippon Medical School Hospital /ID# 166938, Bunkyo-ku, Tokyo, Japan
🇯🇵The University of Tokyo Hospital /ID# 162943, Bunkyo-ku, Tokyo, Japan
🇯🇵Tokyo Medical University Hospital /ID# 164146, Shinjuku-ku, Tokyo, Japan
Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease
- Conditions
- Parkinson's Disease
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Registration Number
- NCT02906488
- Locations
- 🇯🇵
Fukui Red Cross Hospital /ID# 166907, Fukui-shi, Fukui, Japan
🇯🇵National Hospital Organization Takasaki General Medical Center /ID# 207773, Takasaki-shi, Gunma, Japan
🇯🇵Muroran-Clinic /ID# 207780, Muroran-shi, Hokkaido, Japan
Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 15
- Registration Number
- NCT02904902
- Locations
- 🇯🇵
Fukuoka University Hospital /ID# 151350, Fukuoka, Japan
🇯🇵Takagi Dermatological Clinic /ID# 151906, Obihiro, Hokkaido, Japan
🇯🇵Kurume University Hospital /ID# 152579, Kurume-shi, Fukuoka, Japan
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT02899052
- Locations
- 🇺🇸
Oncology Hematology Associates (OHA) - Springfield /ID# 218855, Springfield, Missouri, United States
🇺🇸University of Pennsylvania /ID# 151768, Philadelphia, Pennsylvania, United States
🇺🇸University of Texas Southwestern Medical Center /ID# 218336, Dallas, Texas, United States
A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment
- Conditions
- Axial Spondyloarthritis
- Interventions
- Biological: AdalimumabOther: Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 22
- Registration Number
- NCT02897115